Archive for April, 2014

Cell Therapy Commercialization: Look for Headroom

Author: Mark Curtis, 04/30/14

. Of all the formidable challenges that a biotechnology company will stumble upon in its quest to commercialize, perhaps there is none more frustrating than a failure to get a product reimbursed by payers. After years of navigating the gauntlet of risk that is biotechnology development, and sinking what is likely hundreds of millions of…Read more

Right turn: If you had leukemia or lymphoma, what would you want to know?

Author: Lisa Willemse, 04/25/14

> Julia Pon is a MD/PhD student at the University of British Columbia with an interest in blood cancer. Like many before her, she noticed that the kind of information that is shared with cancer patients is different than what medical students are taught about the disease: one set of information focuses on symptoms and…Read more

No link between STAP cells and acid reflux, except for paper’s authors

Author: Paul Krzyzanowski, 04/22/14

> If you’ve stayed current with the STAP cell fiasco you know it’s been a wild ride. STAP cells, or Stimulus-Triggered Acquisition of Pluripotency cells, caught the imagination of many in late January through their sheer simplicity: You hit cells with a shock of acidic conditions, and they become pluripotent. That’s it. No Yamanaka factors…Read more

Right Turn: Time to stop the bleeding

Author: Roshan Yoganathan, 04/17/14

Recently Revmedx, a pioneer in the biomaterial wound dressing field, made some waves with the commercialization of its product XStatTM . XStatTM received a lot of press because of its FDA approval for use against gunshot wounds and shrapnel-related injuries in the battlefield. It is used to help stop the bleeding and help sustain the…Read more

Testing stem cells in the clinic – a role for publicly funded trials?

Author: David Kent, 04/15/14

> In February this year, the biggest stem cell trial for heart attack patients was begun and will involve over 3000 patients from 11 different countries in Europe. The BAMI trial (the effect of intracoronary reinfusion of Bone marrow-derived mononuclear cells on all course mortality in Acute Myocardial Infarction) aims to demonstrate whether or not…Read more

Right Turn: Bringing stem cells to (fictional) life

Author: Lisa Willemse, 04/11/14

> I’ve been thinking a fair bit about the “personalities” of stem cells in recent weeks — specifically, the characteristics of stem cells that might translate into a persona or a fictional character of some sort. It’s with good reason, of course: The Stem Cell Network is in the process of creating a traveling science…Read more

Cell lines, patient samples, and cultures – oh my!

Author: Sara M. Nolte, 04/08/14

> The thing that is so intriguing about cancer stem cells (CSCs), from a cancer researcher’s perspective, is their powerful potential as therapeutic targets. While CSCs can create or regenerate tumours (causing relapse in some patients despite our best efforts to prevent it – more on this in my previous post on CSCs), they also…Read more

Right Turn: Autism, Stem Cells and the Tooth Fairy

Author: Stacey Johnson, 04/04/14

. This intriguing title is not completely my own. It is a shorter version of Alysson Muotri’s  (UCSD) title from a presentation he gave to the governing Board of the California Institute of Regenerative Medicine on March 13, 2014: “Reversing Autism in the Lab with Help from Stem Cells and the Tooth Fairy.” Dr. Muotri…Read more

The Hunter and the Bear: Italy’s Stamina and Vannoni, as Aesop would have told it

Author: Alessandra Pasut, 04/02/14

Editor’s note: Some of the links included are Italian language sources The case involving Stamina Foundation and the legitimacy of its stem cell treatments has been one of the most discussed and controversial issues in the international stem cell policy scene. Tomorrow, April 3, Davide Vannoni, Stamina’s founder, will be expected at a court trial…Read more